GlassScriptPhysician profile
Michael P Battaglino
NPI 1497894927
$5,882.09
in general payments reported to CMS, 2019-2025
29 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,172 · 2020: $720 · 2021: $659 · 2022: $785 · 2023: $326 · 2024: $151 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,175 · Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,175.00 |
| Food and Beverage | $371.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,258.82 | 2019-2025 | |
| Olympus Medical Systems Corporation | $875.00 | 2025 | Evis Exera III Duodenovideoscope |
| Takeda Pharmaceuticals U.S.A., INC. | $579.06 | 2019-2022 | |
| Biogen, INC. | $450.00 | 2021-2025 | Tysabri |
| Pfizer INC. | $337.81 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $312.58 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $240.14 | 2021-2022 | |
| Shire North American Group INC | $200.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.61 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $149.01 | 2022 | |
| Merck Sharp & Dohme LLC | $147.09 | 2019-2020 | |
| Romark Laboratories, Lc | $123.57 | 2020 | |
| Gilead Sciences, INC. | $118.39 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $103.20 | 2019-2023 | Ocaliva |
| Covidien LP | $103.12 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $76.73 | 2021-2025 | Eterna, Octrode |
| Shionogi INC | $75.75 | 2019-2020 | |
| Medtronic, INC. | $68.35 | 2022 | |
| Janssen Pharmaceuticals, INC | $65.88 | 2019 | |
| Braintree Laboratories, INC. | $62.70 | 2019-2023 | Sutab |
| Ucb, INC. | $53.40 | 2019 | |
| Janssen Biotech, INC. | $49.61 | 2019-2020 | |
| Daiichi Sankyo INC. | $48.47 | 2019 | |
| Boston Scientific Corporation | $45.66 | 2023 | |
| Ferring Pharmaceuticals INC. | $41.73 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $39.71 | 2021 | |
| Genzyme Corporation | $33.58 | 2019-2023 | |
| Intra-Sana Laboratories | $25.43 | 2022 | |
| Qol Medical, LLC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Battaglino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.